PTP inhibitor 1
Names
[ CAS No. ]:
2632-13-5
[ Name ]:
PTP inhibitor 1
[Synonym ]:
α-Bromo-4'-methoxyacetophenone
p-methoxyphenacyl bromide
4'-Methoxyphenacyl Bromide
4-Methoxyphenacyl Br
ω-Bromo-4-methoxyacetophenone
2-Bromo-1-(4-methoxyphenyl)ethanone
4-Methoxyphenacyl bromide
2-Bromo-4′-methoxyacetophenone
2-Bromo-4‘-methoxyacetophenone
Acetophenone, 2-bromo-4'-methoxy-
2-Bromo-4'-methoxyacetophenone
MFCD00465443
2-bromo-1-(4'-methoxy-phenyl)-ethanone
2-Bromo-4'-methoxyacetophenone, Pract.
Ethanone,2-bromo-1-(4-methoxyphenyl)
1-(4-methoxyphenyl)-2-bromo-ethan-1-one
Ethanone, 2-bromo-1-(4-methoxyphenyl)-
EINECS 220-118-8
4-(Bromoacetyl)anisole
Biological Activity
[Description]:
[Related Catalog]:
[Target]
PTP[1]
[In Vitro]
[References]
Chemical & Physical Properties
[ Density]:
1.4±0.1 g/cm3
[ Boiling Point ]:
306.7±17.0 °C at 760 mmHg
[ Melting Point ]:
69-71 °C(lit.)
[ Molecular Formula ]:
C9H9BrO2
[ Molecular Weight ]:
229.071
[ Flash Point ]:
139.3±20.9 °C
[ Exact Mass ]:
227.978592
[ PSA ]:
26.30000
[ LogP ]:
2.27
[ Vapour Pressure ]:
0.0±0.6 mmHg at 25°C
[ Index of Refraction ]:
1.554
[ Storage condition ]:
2-8°C
MSDS
Safety Information
[ Symbol ]:
GHS05, GHS07
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H314-H335
[ Precautionary Statements ]:
P261-P280-P305 + P351 + P338-P310
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
[ Hazard Codes ]:
Xi:Irritant
[ Risk Phrases ]:
R36/37/38
[ Safety Phrases ]:
S26-S27-S28-S36/37/39-S45-S37/39
[ RIDADR ]:
UN 3261 8/PG 2
[ WGK Germany ]:
3
[ Packaging Group ]:
III
[ Hazard Class ]:
8
[ HS Code ]:
29147090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2914700090
[ Summary ]:
HS: 2914700090 halogenated, sulphonated, nitrated or nitrosated derivatives of ketones and quinones, whether or not with other oxygen function Tax rebate rate:9.0% Supervision conditions:none VAT:17.0% MFN tariff:5.5% General tariff:30.0%
Articles
J. Med. Chem. 54 , 4042-56, (2011)
Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, bein...
QSAR study and conformational analysis of 4-arylthiazolylhydrazones derived from 1-indanones with anti-Trypanosoma cruzi activity.Eur. J. Pharm. Sci. 78 , 190-7, (2015)
A set of 4-arylthiazolylhydrazones derived from 1-indanones (TZHs) previously synthesized and assayed against Trypanosoma cruzi, the causative agent of Chagas disease, were explored in terms of confor...
Synthesis of diblock copolymers bearing p-methoxyphenacyl side groups.Polym. Chem. 2(10) , 2284-2292, (2011)